These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
174 related articles for article (PubMed ID: 14505242)
1. [Cellular therapy in neurodegenerative diseases: perspective from the experimental model of Parkinson's disease]. Sánchez Pernaute R Neurologia; 2003 Sep; 18(7):355-6. PubMed ID: 14505242 [No Abstract] [Full Text] [Related]
2. Olfactory mucosa is a potential source for autologous stem cell therapy for Parkinson's disease. Murrell W; Wetzig A; Donnellan M; Féron F; Burne T; Meedeniya A; Kesby J; Bianco J; Perry C; Silburn P; Mackay-Sim A Stem Cells; 2008 Aug; 26(8):2183-92. PubMed ID: 18535154 [TBL] [Abstract][Full Text] [Related]
3. Stem cell-based therapy for Parkinson's disease. Correia AS; Anisimov SV; Li JY; Brundin P Ann Med; 2005; 37(7):487-98. PubMed ID: 16278162 [TBL] [Abstract][Full Text] [Related]
8. [Restoration of brain function by cell transplantation]. Kakishita K; Nakao N; Itakura T Nihon Rinsho; 2003 Mar; 61(3):457-62. PubMed ID: 12701173 [TBL] [Abstract][Full Text] [Related]
9. Transplantation of embryonic stem cell-derived dopaminergic neurons in MPTP-treated monkeys. Takahashi J; Takagi Y; Saiki H Methods Mol Biol; 2009; 482():199-212. PubMed ID: 19089358 [TBL] [Abstract][Full Text] [Related]
10. [Cell replacement therapy with human ES cells for the treatment of Parkinson's disease]. Takahashi J No Shinkei Geka; 2007 Sep; 35(9):935-43. PubMed ID: 17867315 [No Abstract] [Full Text] [Related]
11. Rescuing defective vesicular trafficking protects against alpha-synuclein toxicity in cellular and animal models of Parkinson's disease. Lashuel HA; Hirling H ACS Chem Biol; 2006 Aug; 1(7):420-4. PubMed ID: 17168518 [TBL] [Abstract][Full Text] [Related]
12. Adult stem cells for neuronal repair. Barzilay R; Levy YS; Melamed E; Offen D Isr Med Assoc J; 2006 Jan; 8(1):61-6. PubMed ID: 16450758 [No Abstract] [Full Text] [Related]
13. Role of transcription factors in cell replacement therapies for neurodegenerative conditions. Thomas M Regen Med; 2010 May; 5(3):441-50. PubMed ID: 20455654 [TBL] [Abstract][Full Text] [Related]
14. [Neuronal death and growth factors: new therapeutic approaches in Parkinson's disease]. Wider C; Burkhard PR; Sajadi A; Vingerhoets FJ Rev Med Suisse; 2006 May; 2(64):1158-62. PubMed ID: 16734187 [TBL] [Abstract][Full Text] [Related]
15. Regenerative medicine in Parkinson's disease: generation of mesencephalic dopaminergic cells from embryonic stem cells. Taylor H; Minger SL Curr Opin Biotechnol; 2005 Oct; 16(5):487-92. PubMed ID: 16143504 [TBL] [Abstract][Full Text] [Related]
16. Stem cells may reshape the prospect of Parkinson's disease therapy. Sonntag KC; Simantov R; Isacson O Brain Res Mol Brain Res; 2005 Mar; 134(1):34-51. PubMed ID: 15790528 [TBL] [Abstract][Full Text] [Related]
17. Factors involved in the determination of the neurotransmitter phenotype of developing neurons of the CNS: applications in cell replacement treatment for Parkinson's disease. Riaz SS; Bradford HF Prog Neurobiol; 2005 Jul; 76(4):257-78. PubMed ID: 16256257 [TBL] [Abstract][Full Text] [Related]
18. Cell therapy for Parkinson's disease: problems and prospects. Björklund A Novartis Found Symp; 2005; 265():174-86; discussion 187, 204-211. PubMed ID: 16050257 [TBL] [Abstract][Full Text] [Related]
19. Assessing fetal nerve cell grafts in Parkinson's disease. Braak H; Del Tredici K Nat Med; 2008 May; 14(5):483-5. PubMed ID: 18463652 [No Abstract] [Full Text] [Related]